Matches in SemOpenAlex for { <https://semopenalex.org/work/W2508973811> ?p ?o ?g. }
- W2508973811 endingPage "63387" @default.
- W2508973811 startingPage "63374" @default.
- W2508973811 abstract "// Yongqian Gao 1, * , Jinyi Li 2, * , Na Qiao 3, * , Qingsong Meng 3 , Ming Zhang 3 , Xin Wang 3 , Jianghua Jia 3 , Shuwen Yang 3 , Changbao Qu 3 , Wei Li 3 , Dongbin Wang 3 1 Department of Interventional Radiology, Tangshan Gongren Hospital, Hebei Medical University, Tangshan 063000, P.R. China 2 Department of Urology, Icahn School of Medicine at Mount Sinai, New York, 10029, USA 3 Department of Urologic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China * These authors contributed equally to this work Correspondence to: Dongbin Wang, email: dongbin.wang@outlook.com Keywords: renal cell carcinoma, adrenomedullin, tyrosine kinase inhibitor, ERK Received: April 29, 2016 Accepted: August 13, 2016 Published: August 22, 2016 ABSTRACT Purpose: To evaluate the mechanisms underlying sunitinib resistance in RCC and to identify targets that may be used to overcome this resistance. Results: Reanalysis of transcriptome microarray datasets (GSE64052 and GSE76068) showed that adrenomedullin expression was increased in sunitinib-resistant tumors. And adrenomedullin expression was increased in sunitinib-resistant tumor xenografts, accompanied by upregulation of phospho-ERK levels. However, blocking adrenomedullin inhibited sunitinib-resistant tumor growth. Treatment of RCC cells with sunitinib and ADM22-52 was superior to monotherapy with either agent. Additionally, adrenomedullin upregulated cAMP and activated the ERK/MAPK pathway, promoting cell proliferation, while knockdown of adrenomedullin inhibited RCC cell growth and invasion in vitro . Materials and methods: We searched the Gene Expression Omnibus (GEO) database to find data regarding sunitinib-resistant RCC. These data were subsequently reanalyzed to identify targets that contribute to sunitinib resistance, and adrenomedullin upregulation was found to mediate sunitinib resistance in RCC. Then, we created an RCC mouse xenograft model. Mice were treated with sunitinib, an adrenomedullin receptor antagonist (ADM22-52), a MEK inhibitor (PD98059) and different combinations of these three drugs to investigate their effects on tumor growth. RCC cells (786-0) were cultured in vitro and treated with an ADM22-52 or PD98059 to determine whether adrenomedullin activates the ERK/MAPK pathway. Adrenomedullin was knocked down in 786-0 cells via siRNA, and the effects of this knockdown on cell were subsequently investigated. Conclusions: Adrenomedullin plays an important role in RCC resistance to sunitinib treatment. The combination of sunitinib and an adrenomedullin receptor antagonist may result in better outcomes in advanced RCC patients." @default.
- W2508973811 created "2016-09-16" @default.
- W2508973811 creator A5006822602 @default.
- W2508973811 creator A5011354330 @default.
- W2508973811 creator A5013152754 @default.
- W2508973811 creator A5014822028 @default.
- W2508973811 creator A5016903781 @default.
- W2508973811 creator A5029776179 @default.
- W2508973811 creator A5033623552 @default.
- W2508973811 creator A5039359445 @default.
- W2508973811 creator A5070384577 @default.
- W2508973811 creator A5082035312 @default.
- W2508973811 creator A5082726995 @default.
- W2508973811 date "2016-08-22" @default.
- W2508973811 modified "2023-10-18" @default.
- W2508973811 title "Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway" @default.
- W2508973811 cites W1547252551 @default.
- W2508973811 cites W1678138068 @default.
- W2508973811 cites W1976779081 @default.
- W2508973811 cites W1977999028 @default.
- W2508973811 cites W1979842614 @default.
- W2508973811 cites W1988826649 @default.
- W2508973811 cites W1989419353 @default.
- W2508973811 cites W1992476560 @default.
- W2508973811 cites W2001084206 @default.
- W2508973811 cites W2006480812 @default.
- W2508973811 cites W2010734080 @default.
- W2508973811 cites W2013443224 @default.
- W2508973811 cites W2017322644 @default.
- W2508973811 cites W2019763234 @default.
- W2508973811 cites W2037957813 @default.
- W2508973811 cites W2044670221 @default.
- W2508973811 cites W2045992174 @default.
- W2508973811 cites W2054835096 @default.
- W2508973811 cites W2062555123 @default.
- W2508973811 cites W2071577747 @default.
- W2508973811 cites W2087201383 @default.
- W2508973811 cites W2092419989 @default.
- W2508973811 cites W2096439168 @default.
- W2508973811 cites W2099088585 @default.
- W2508973811 cites W2099355499 @default.
- W2508973811 cites W2105885380 @default.
- W2508973811 cites W2116490375 @default.
- W2508973811 cites W2116634113 @default.
- W2508973811 cites W2122930661 @default.
- W2508973811 cites W2123312554 @default.
- W2508973811 cites W2144169031 @default.
- W2508973811 cites W2148802162 @default.
- W2508973811 cites W2155319477 @default.
- W2508973811 cites W2157196932 @default.
- W2508973811 cites W2164638888 @default.
- W2508973811 cites W2190491604 @default.
- W2508973811 cites W2206860290 @default.
- W2508973811 cites W2403231832 @default.
- W2508973811 cites W4236535992 @default.
- W2508973811 doi "https://doi.org/10.18632/oncotarget.11463" @default.
- W2508973811 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5325371" @default.
- W2508973811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27556517" @default.
- W2508973811 hasPublicationYear "2016" @default.
- W2508973811 type Work @default.
- W2508973811 sameAs 2508973811 @default.
- W2508973811 citedByCount "15" @default.
- W2508973811 countsByYear W25089738112017 @default.
- W2508973811 countsByYear W25089738112018 @default.
- W2508973811 countsByYear W25089738112019 @default.
- W2508973811 countsByYear W25089738112020 @default.
- W2508973811 countsByYear W25089738112021 @default.
- W2508973811 countsByYear W25089738112023 @default.
- W2508973811 crossrefType "journal-article" @default.
- W2508973811 hasAuthorship W2508973811A5006822602 @default.
- W2508973811 hasAuthorship W2508973811A5011354330 @default.
- W2508973811 hasAuthorship W2508973811A5013152754 @default.
- W2508973811 hasAuthorship W2508973811A5014822028 @default.
- W2508973811 hasAuthorship W2508973811A5016903781 @default.
- W2508973811 hasAuthorship W2508973811A5029776179 @default.
- W2508973811 hasAuthorship W2508973811A5033623552 @default.
- W2508973811 hasAuthorship W2508973811A5039359445 @default.
- W2508973811 hasAuthorship W2508973811A5070384577 @default.
- W2508973811 hasAuthorship W2508973811A5082035312 @default.
- W2508973811 hasAuthorship W2508973811A5082726995 @default.
- W2508973811 hasBestOaLocation W25089738111 @default.
- W2508973811 hasConcept C104317684 @default.
- W2508973811 hasConcept C121608353 @default.
- W2508973811 hasConcept C126322002 @default.
- W2508973811 hasConcept C127561419 @default.
- W2508973811 hasConcept C170493617 @default.
- W2508973811 hasConcept C173396325 @default.
- W2508973811 hasConcept C184235292 @default.
- W2508973811 hasConcept C2777152744 @default.
- W2508973811 hasConcept C2777472916 @default.
- W2508973811 hasConcept C2778019345 @default.
- W2508973811 hasConcept C2778695046 @default.
- W2508973811 hasConcept C2779490328 @default.
- W2508973811 hasConcept C2781018059 @default.
- W2508973811 hasConcept C2781278892 @default.
- W2508973811 hasConcept C29537977 @default.
- W2508973811 hasConcept C502942594 @default.
- W2508973811 hasConcept C54355233 @default.